How much do GLP-1s cost per month?

It depends entirely on how you pay. With insurance coverage, a copay is often $50-$150 a month. Compounded semaglutide or tirzepatide through a telehealth service typically runs $200-$500 a month, though those versions are not FDA-approved. The branded cash price is the full list price, which is why most people do not pay it.

Is compounded semaglutide cheaper than Wegovy?

It has historically been cheaper, in the $200-$500 per month range versus the branded list price. But the FDA declared the semaglutide shortage resolved in February 2025, and the deadlines for compounding under that exemption have passed. Compounded semaglutide is not FDA-approved and is now limited to patient-specific preparations with a documented clinical reason. Price is not the variable that decides this one.

What should I ask before signing up for a GLP-1 program?

Ask whether the medication is brand or compounded, what the total monthly cost including shipping and any membership fee is, what happens to your price if you change doses or stop, and whether there are intake, monitoring, or program fees.

Guides

How Much Do GLP-1s Cost? Real Prices vs. Advertised Prices

Q: What should you ask before starting a GLP-1 program?

Is this brand or compounded? If compounded, what is the documented clinical reason I cannot use the approved product? (Compounded is not FDA-approved.) What is the total monthly cost including shipping and any membership fee? What happens to my price if I change doses or stop? Are there hidden fees — intake, monitoring, 'program' fees?

The gap between list price and what people actually pay — and why the sticker price is the least important number.

Published August 20, 2026Updated September 12, 202610 min readWritten and fact-checked against the sources below

Read this first

Prices change monthly and vary by state and provider. This is general education, not a quote. Compounded GLP-1s are not FDA-approved, and since the 2025 shortage delistings they can only be dispensed in narrow, patient-specific circumstances.

The single most misleading number in GLP-1 pricing is the list price — the sticker price on the branded drug. It has almost nothing to do with what you'll actually pay, and it's why 'GLP-1s cost $1,300 a month' headlines are technically true and practically useless.

What are the ways people pay for GLP-1s?

1.Brand + insurance — if your plan covers it, your share is a copay (often $50–$150/mo), but prior authorization and step therapy are common.
2.Brand cash price — the full list price, which is why most people don't go this route.
3.Compounded — historically $200–$500/mo through telehealth. Since the 2025 shortage delistings this is no longer a routine option: it is limited to patient-specific preparations where a prescriber documents a clinically significant difference. Not FDA-approved.
4.Cash-pay brand (discounts) — manufacturer savings cards and pharmacy discount programs can cut brand cost substantially for commercial-insurance holders.

Why is the list price different from what you pay?

List prices are set by manufacturers and reflect negotiation leverage, not cost. What you pay is determined by your insurer's formulary, your copay tier, or — for compounded — the telehealth service's own pricing. Two people with identical diagnoses can pay wildly different amounts.

What should you ask before starting a GLP-1 program?

Is this brand or compounded? If compounded, what is the documented clinical reason I cannot use the approved product? (Compounded is not FDA-approved.)
What is the total monthly cost including shipping and any membership fee?
What happens to my price if I change doses or stop?
Are there hidden fees — intake, monitoring, 'program' fees?

Common questions about GLP-1 cost

How much do GLP-1s cost per month?: It depends entirely on how you pay. With insurance coverage, a copay is often $50-$150 a month. Compounded semaglutide or tirzepatide through a telehealth service typically runs $200-$500 a month, though those versions are not FDA-approved. The branded cash price is the full list price, which is why most people do not pay it.
Why is the list price so different from what people pay?: List prices are set by manufacturers and reflect negotiation leverage, not cost. What you actually pay is determined by your insurer's formulary, your copay tier, or the telehealth service's own pricing. Two people with identical diagnoses can pay wildly different amounts.
Is compounded semaglutide cheaper than Wegovy?: It has historically been cheaper, in the $200-$500 per month range versus the branded list price. But the FDA declared the semaglutide shortage resolved in February 2025, and the deadlines for compounding under that exemption have passed. Compounded semaglutide is not FDA-approved and is now limited to patient-specific preparations with a documented clinical reason. Price is not the variable that decides this one.
What should I ask before signing up for a GLP-1 program?: Ask whether the medication is brand or compounded, what the total monthly cost including shipping and any membership fee is, what happens to your price if you change doses or stop, and whether there are intake, monitoring, or program fees.

Bottom line

Don't compare GLP-1s by list price. Compare total monthly cost, brand vs. compounded status, and hidden fees. And know that compounded versions are not FDA-approved — and that since 2025 they are only appropriate where a prescriber has documented a patient-specific clinical reason. This is education, not a price quote.

Want this handled for you?

LunaRx — clinician-led GLP-1 care with a plan to come off

LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.

Start the 2-minute eligibility checkIndependent site · by LunaRx · not medical advice

Sources

Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.

1.
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · 2025
Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.
2.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A
U.S. Food and Drug Administration, guidance for industry · 2018
A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.
3.
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. Food and Drug Administration · 2026
April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.

Get the weekly research update

New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.

Unsubscribe anytime. Read our privacy policy.